Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/692,764
IN.	IFORMATIO	N DIS	SCLOSURE	Filing Date	October 24, 2003
S	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Stuart B. Levy
				Art Unit	1633
				Examiner Name	Janet L. Epps Smith
Sheet	1	of	1	Attorney Docket Number	16534-539001US

U.S. PATENT DOCUMENTS				
Cite No. ¹	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Cite No. ¹	Cito	Cite Document Number Publication Date	Cite Document Number Publication Date Name of Patentee or

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (ff known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Τ ⁶
	Α	EP-1241160-A1	09-18-2002	Glaxo Group Ltd		
	В	WO-03/030819-A2	04-17-2003	Tetragenex Pharmaceuticals Inc et al.		
	С	WO-99/30720-A1	06-24-1999	Univ New York		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	D	Wilson, R. G., et al., "Comparative Inhibition of Nuclear RNA Synthesis in Cultured Mouse Leukemia L1210 Cells by Adriamycin and 4'-Epi-Adriamyclin", <i>Chemico-Biological Interactions</i> , 37(3), pgs. 351-363 (1981)	
	Е	Chuang, L.F., et al., "Selective Inhibition of Eukaryotic RNA Polymerase: A Possible New Mechanism of Antitumor Drug Action", <i>Database Medline (Online), US National Library of Medicine (NLM)</i> , Bethesda, MD, US (1984)	

Examiner	/land Enna Cmith/	Date
Signature	/Janet Epps Smith	Considered 05/20/2011

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. § Applicant is to place a check mark here if English language Translation is attached.

5017759v.1